ArticleMolecular biology reports2025
Expression of thrombomodulin in pterygium: implications for inflammation and disease progression.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPterygium is a chronic inflammatory condition of conjunctiva. Thrombomodulin (TM) is a glycoprotein involved in the regulation of inflammation. This study investigated TM expression in primary and recurrent pterygium compared to normal conjunctiva, along with its role in pterygium pathogenesis and potential as a therapeutic target for inflammation control. METHODS AND
resultsPterygium (10 primary, 10 recurrent) and normal conjunctiva specimens were collected from 20 patients who underwent pterygium excision. TM expression was analyzed using immunofluorescence, western blotting, and real-time quantitative polymerase chain reaction (RT-PCR). Inflammatory markers, including interleukin-6 (IL-6), high mobility group box 1 (HMGB1), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinase-1 (MMP-1), were measured. The results showed significantly lower TM expression in pterygium tissues (p < 0.01), with higher TM levels in the head region compared to the body, suggesting a localized inflammatory response. Additionally, macrophage marker F4/80 and neutrophil marker NIMP-R14 were elevated in pterygium tissues. Western blot and RT-PCR confirmed significantly reduced TM expression (p < 0.0001) in primary and recurrent pterygium, with recurrent cases showing even lower levels (p < 0.05). Elevated IL-6, HMGB1, VEGF, bFGF, and MMP-1 levels suggest a strong association between TM downregulation and increased inflammation.
conclusionsTM downregulation in pterygium (particularly in recurrent cases) may contribute to chronic inflammation and disease progression. Upregulation of TM at the pterygium head may represent a localized protective response against inflammation. TM supplementation should be explored as a novel therapeutic strategy to mitigate inflammation in pterygium.
Indexed as
Identifiers
40397236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.